6 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
inhibitors in CVD ... and CKD. ... in HFrEF on GDMT ... outcomes in HFrEF ... visualabstract #table #CVD
Oral Antihypertensive Medications - Selection by Comorbidities
Comorbidities: 
 • Stable Angina, HFpEF, HFrEF, AFib, TAA/Marfan, Aortic
Antihypertensive Medications ... Stable Angina, HFpEF ... , HFrEF, AFib, TAA ... Dissection • CKD ... pharmacology #table #management
Stages in the development of HF and recommended therapy by stage. ACEI indicates angiotensin-converting enzyme inhibitor;
angiotensin-receptor blocker; CAD ... ejection fraction; GDMT ... HFpEF, heart failure ... ejection fraction; HFrEF ... #CHF #Congestive
Heart Failure (HFrEF) Treatment - GDMT for stage C 

For patients with Heart Failure with REDUCED
Heart Failure (HFrEF ... Ejection Fraction (HFrEF ... patients with HFrEF ... #HFrEF #Pharmacology ... #Management #Treatment
Guideline-Directed Medical Therapy (GDMT) in HFrEF and CKD

 • Class I pillars of HFrEF GDMT across
) in HFrEF and CKD ... therapies" for HFrEF ... Chronotropes • Medications ... used in HFrEF: ... #CKD #HFrEF #management
Pathophysiological mechanisms of diastolic heart failure HFpEF and possible therapeutic interventions.
Hypertension → Overload
Diabetes → Oxidative stress,
mechanisms of diastolic heart ... failure HFpEF and ... RAGE activation CAD ... #heartfailure #dchf ... #hfpef #pathophysiology